|
|
|
|
|
|
|
Overcoming The Obstacles Of Spray-Dried Dispersion Scale-Up
|
Scaling spray-dried dispersions from feasibility to commercial manufacture introduces compounding risks to bioavailability, yield, and physical stability. This white paper examines a material-sparing, model-based approach that uses mechanistic and empirical predictive tools to characterize process sensitivities before late-stage development begins, with a case study showing how the methodology performed on a molecule with challenging physical and chemical properties.
|
|
|
|
|
|
|
|
Why Spray Drying Is Gaining Attention
|
|
Article | By Dr. Richard Johnson, Upperton Pharma Solutions
|
Facing patent cliffs, pharma companies can leverage spray drying to reformulate complex biologics, enabling non-invasive delivery, boosting patient convenience, and securing new patents.
|
|
|
|
|
|
|
|
Straight From The Source: A Live Q&A
|
|
Webinar | AustinPx
|
Experts discuss a solvent-free fusion process for amorphous solid dispersions, highlighting formulation flexibility, scale-up, process control, and early strategies to reduce risk and support commercialization.
|
|
|
|
|
|
|
|
By Louis Garguilo, Chief Editor, Outsourced Pharma
|
In-person events should be a tool for separating the noise from authentic signals. Through “content design,” the best conferences provide you direct market insights via information aggregation, discussion, and business meetings. The founders of CDMO Live conferences speak with Chief Editor Louis Garguilo on “curating" events for optimal development and manufacturing outsourcing outcomes. In short: No wasted words; no wasted time.
|
|
|
|
|
|
Building A Sterile Manufacturing Program For Annex 1 Compliance
|
|
By Bikash Chatterjee, president and CSO of Pharmatech Associates, a USP Company and USP Microbiology
|
In this third and final article of this series, let's take a closer look at what a well-constructed Annex 1-compliant program looks like at each stage, from gap assessment through governance.
|
|
|
|
INDUSTRY INSIGHTS CONTINUED
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE
|
|
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.
|
|
|
| Connect With Outsourced Pharma: |
|
|
|
|
